Published by the European Cannabis Institute · Educational and professional reference content.
Oromucosal sprays combine a medicinal formulation with a delivery device. Quality therefore depends on both the liquid and the performance of the pump, actuator and container system.
Delivered-dose consistency
Testing should assess the amount delivered per actuation, priming requirements, dose uniformity through container life and the effect of orientation or handling.
Formulation risks
Solvent composition, viscosity, precipitation, flavouring and excipient compatibility can affect spray pattern, dose delivery and patient acceptability.
Microbiological strategy
Multi-dose systems need a justified approach to microbial control, preservative effectiveness where applicable and in-use shelf life.
Human factors
Instructions should clearly address priming, storage, cleaning, missed doses and end-of-container behaviour. Device usability is a quality attribute, not only a marketing consideration.
ECI perspective
Strong cannabis quality systems connect scientific evidence, product knowledge, validated methods and controlled operations. Organisations should document the rationale for their decisions and update it as evidence, processes and regulatory expectations evolve.
References
- Ph. Eur. — Oromucosal Preparations, General Monograph
- EMA Guideline on Quality of Oral Modified Release Products (device reference)
- ICH Q8(R2) — Pharmaceutical Development
Confirm the current effective version and national applicability before operational, regulatory or clinical use.